% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • mining_phd mining_phd Oct 26, 2012 11:26 AM Flag

    Why I favor CYCC over SNSS


    It is my view that SNSS's Voreloxin will have great difficulty competing with CYCC. First of all, their study is being combined w/ Cytarabine for refractory AML. This is a flawed strategy. Refractory patients will be too frail for this type of regimen and will never initiate such treatment. SAPA/DAC will ultimately be approved for front line AML and due to the lower toxicity of this regimen, no better long term maintenance drug combination other than SAPA/DAC will be available. The hint of this is the huge reduction in the 60 day mortality rate in the SAPA/DAC pilot arm study. I believe this hypothesis will be confirmed by the mature data of the Seamless pilot arm which will available by the end of this year. As a side note, Voreloxin has a rather nasty side effect of muccocystic oral lesions and is IV administered.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.9339+0.0440(+4.94%)Nov 25 4:00 PMEST